Latest Funding News

TruScreen Group has secured NZ$1.82 million through an oversubscribed placement, underscoring investor confidence amid its global cervical screening expansion. The company also announced a renounceable rights issue and attaching options, both subject to shareholder approval.

EROAD reported flat group revenue of NZD 195.2 million for FY26, driven by strong Australian growth and steady New Zealand performance, offset by a North American decline and a hefty goodwill impairment.

Alternative Investment Trust (AIQ) has issued 7.39 million units at A$1.38 each, raising A$10.2 million from wholesale investors without a product disclosure statement. The capital raise aligns with AIQ’s adjusted net tangible asset value and complies with Corporations Act requirements.

Gumtree Australia Markets has refinanced its Commonwealth Bank loan, cutting quarterly repayments and extending the facility to November 2027, freeing up cashflow to support sales growth.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

Orion Minerals has secured $15.4 million in a placement to accelerate development at its Prieska and Okiep copper projects in South Africa, paving the way for its transition to a copper producer.

Mayne Pharma has been awarded $13.27 million in legal costs by the Supreme Court of New South Wales after successfully defending against Cosette Pharmaceuticals’ claims tied to a terminated acquisition deal.

Codan Limited is acquiring the intellectual property of US-based Adaptive Dynamics to enhance its electronic warfare and mission-critical communications capabilities, aiming to strengthen its position in next-generation defence programs.

Ballymore Resources has pushed the boundaries of its Torpy’s silver-lead-zinc-indium discovery in North Queensland, with initial results from a fresh 3,000m drilling campaign revealing broad zones of massive sulphide mineralisation closer to surface. Assays are due in June, while a government-backed gravity survey aims to unlock further targets across the Ruddygore corridor.

TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.

Godolphin Resources is spinning out its Narraburra Rare Earths Project into a new ASX-listed entity, Matrix Critical Minerals, with MST Financial appointed to spearhead the IPO expected in the second half of 2026.

Arafura Rare Earths launches a two-tranche A$350 million placement and a A$25 million share purchase plan, closing the equity funding gap for its Nolans Rare Earths Project ahead of construction.